

REMARKS/ARGUMENTS

In response to the new set of requirements for restriction and sequence election, Applicants elect without traverse to prosecute the invention of Group V, drawn to a method of selling and/or licensing, with further restriction to nucleic acids having the sequence set forth in SEQ ID NO: 14193, and when a plurality of probes is appropriate to the context, additionally to nucleic acids having the sequence set forth in SEQ ID NO: 14542. Applicants reserve the right to prosecute any subject matter not examined here in one or more divisional application(s).

All of claims 54-109 are drawn to restriction Group V. Of these claims, claims 71- 73, 86-88 and 107-109 further read on the elected SEQ ID NOs.

Support for the claims newly added by amendment herein may be found throughout the specification as filed and original claims; no new matter has been added.


Appl. No. 10/029,386
Amendment dated February 23, 2004
Reply to Office action of January 29, 2004

Early and favorable action is earnestly solicited.

Respectfully submitted,

AMERSHAM BIOSCIENCES CORP


By:


Xonggang Ji
Registration No.: 53,073
Agent for Applicants

Amersham Biosciences Corp
800 Centennial Avenue
P. O. Box 1327
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875
Fax: (732) 457-8463

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on February 23, 2004.

Signature: 

Name: Melissa Leck